Welcome to our dedicated page for ORTHOPEDIATRICS SEC filings (Ticker: KIDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ORTHOPEDIATRICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ORTHOPEDIATRICS's regulatory disclosures and financial reporting.
OrthoPediatrics Corp. reported Q2 2026 net revenue of $70.5 million, up 15% from $61.1 million, with first‑half revenue rising 14% to $129.9 million. Growth was led by trauma and deformity products, where Q2 sales increased 26% to $52.6 million, while scoliosis Q2 revenue declined 9% to $16.9 million. Gross margin improved to 74% from 72% for both the quarter and year‑to‑date.
Q2 operating loss narrowed to $4.1 million from $10.7 million, but higher interest expense turned prior‑year other income into expense, leaving Q2 net loss essentially flat at $7.2 million (EPS $(0.30)). First‑half net loss was $17.9 million, or $(0.75) per share. At June 30, 2026, cash, restricted cash and short‑term investments totaled $47.9 million against total debt of $105.8 million, including a $51.0 million term loan and $50.0 million of 4.75% convertible notes due 2030. Net cash used in operating activities improved to $2.4 million from $14.6 million a year earlier. Management states that existing cash, expected cash flows and an undrawn $20.0 million delayed draw term loan under the Braidwell amendment are expected to support operations for more than 12 months.
OrthoPediatrics Corp., a company focused exclusively on pediatric orthopedics, presents an investor update highlighting a $6.2B global addressable market and a strategy centered on child-specific implants, a broad product portfolio, global sales coverage and extensive clinical education for pediatric orthopedic surgeons.
The company reports steady revenue expansion, with 2025 revenue of $236.3 million versus $204.7 million in 2024, and 2Q 2026 revenue of $70.5 million compared with $61.1 million in 2Q 2025. Despite growth, OrthoPediatrics continues to post net losses, including a 2025 diluted EPS of $(1.69).
Management provides 2026 guidance for revenue of $265.0–$269.0 million, Adjusted EBITDA of approximately $25.0 million and roughly breakeven free cash flow. As of June 30, 2026, the balance sheet shows $47.9 million in cash and short-term investments and $99.6 million of debt. The presentation also outlines a multi-year “super-cycle” of differentiated pediatric product launches and explains non-GAAP measures such as Adjusted EBITDA, adjusted diluted loss per share and free cash flow used in assessing operating performance.
OrthoPediatrics Corp. reported record second-quarter 2026 net revenue of $70.5 million, up 15% from $61.1 million a year earlier, driven by 26% growth in Trauma and Deformity products and 22% international revenue growth. U.S. revenue was $54.8 million and international revenue $15.7 million. Gross profit rose to $52.4 million with margin improving to 74% from 72%.
Adjusted EBITDA reached a record $6.8 million versus $4.1 million in 2025, while net loss was $7.2 million, or $0.30 per share, similar to the prior year. Free cash flow usage in the quarter improved to $3.1 million from $13.9 million. The company raised full-year 2026 revenue guidance to $265.0–$269.0 million, reiterated expected adjusted EBITDA of about $25.0 million, and continues to target breakeven free cash flow in 2026.
Integrated Core Strategies (US) LLC and related Millennium entities reported beneficial ownership of OrthoPediatrics Corp. common stock on a Schedule 13G/A. Integrated Core Strategies (US) LLC reports 811,042 shares, representing 3.2% of the common stock with shared voting and dispositive power only.
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report beneficial ownership of 816,830 shares, also equal to 3.2% of the class, with no sole voting or dispositive power. The filers state they collectively own 5 percent or less of the class and clarify that their control relationships do not, by themselves, constitute an admission of beneficial ownership. A joint filing agreement among the four reporting persons is included.
Pelizzon David R reported acquisition or exercise transactions in this Form 4 filing.
OrthoPediatrics Corp director David R. Pelizzon received an award of 11,436 shares of common stock on June 9, 2026. The shares were granted at no cost as a stock award, increasing his direct holdings to 44,384 common shares, including 17,959 restricted stock awards.
The filing also reports 6,901,764 common shares held indirectly through Squadron Capital LLC. As President and a member of Squadron’s Managing Committee, Pelizzon may be deemed a beneficial owner, but he expressly disclaims beneficial ownership except for his pecuniary interest.
OrthoPediatrics Corp director Bryan W. Hughes received a stock award of 11,436 shares of common stock. The shares were granted at no cash cost as equity compensation, rather than bought on the open market. After this award, his direct holdings total 32,663 shares.
A footnote explains that these holdings include restricted stock awards totaling 17,959 shares, which typically vest over time subject to conditions. The filing reports only this grant transaction and does not show any share sales or option exercises.
ORTHOPEDIATRICS CORP director Kelly Laine Fischer received a stock-based compensation grant. On June 9, 2026, Fischer was awarded 11,436 shares of Common Stock at $0.00 per share, reported as a grant or other acquisition rather than an open-market purchase.
Following this award, Fischer’s directly held position totals 15,781 shares, which the filing notes includes restricted stock awards. The transaction reflects routine equity compensation for a director and does not represent a discretionary market trade in the company’s shares.
Riccitelli Samuel D reported acquisition or exercise transactions in this Form 4 filing.
ORTHOPEDIATRICS CORP director Samuel D. Riccitelli received a stock grant of 11,436 shares of Common Stock. The award was granted at no cash cost per share and is held directly. Following this grant, he directly owns 31,859 shares, including restricted stock awards totaling 17,959 shares.
Ruf Harold reported acquisition or exercise transactions in this Form 4 filing.
OrthoPediatrics Corp director Harold Ruf reported a stock award of 11,436 shares of common stock. The award was granted at a price of $0.00 per share as equity compensation, not an open-market purchase.
Following the grant, Ruf directly holds 19,837 shares of common stock. The filing also reports indirect holdings of 2,400 shares through The Last Chance Legacy Trust and 19,247 shares through the Harald Ruf Roth IRA, where he is deemed to have a pecuniary interest under Section 16 regulations. Certain positions include restricted stock awards noted in the footnotes.
Bailey David R reported acquisition or exercise transactions in this Form 4 filing.
ORTHOPEDIATRICS CORP President and CEO David R. Bailey received a grant of 119,140 shares of Common Stock on June 9, 2026. The award was reported at a price of $0.00 per share, indicating a stock-based compensation grant rather than an open-market purchase.
Following this grant, Bailey directly holds 417,160 shares of the company’s Common Stock. The holdings include restricted stock awards totaling 307,031 shares, which typically vest over time and are subject to continued service or performance conditions.